Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: J Immunother. 2012 Jul;35(6):502–512. doi: 10.1097/CJI.0b013e3182619c8e

Figure 3.

Figure 3

MDSCs, MMP activity and the profile of inflammatory factors in timp2−/− tumors. (A) Representative tumor sections immune stained for CD11b+, Gr-1+ showing MDSCs (yellow fluorescence) in tumors from WT and timp-2−/− mice, nuclei counter stained with DAPI. Scale bar= 60μm. (B) Number of MDSCs per high power field (20×) in timp2−/− tumors versus WT (4 tumors in each group, n=16, mean ± SD) (C) MMP activation shown as red emission of cleaved infrared-tagged peptide substrate by tumor cells (arrows), MMP activity demonstrated by FITC-Gr-1+ cells in timp2−/− tumors (yellow emission) versus WT tumors, nuclei counter-stained with DAPI. Scale bar= 20 μm. (D) Heat map showing differential gene expression higher than two (> 2) of inflammatory factors tumors from timp-2−/− mice versus WT tumors (n =3 in each groups). (E) Fold change in inflammatory factors from timp2−/− tumors over WT tumors (significant change in three tumors in each group, *p< 0.005).

HHS Vulnerability Disclosure